Sphingolipid-like Molecules Reverse Mitochondrial Fragmentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for metabolic disorders such as obesity, type 2 diabetes, and mitochondrial fragmentation are inadequate, as they fail to effectively address the underlying mitochondrial dysfunction and leptin resistance associated with high-fat diets.

Innovation Solution

The use of sphingolipid-like molecules, specifically compounds like 893, which inhibit ARF6 and PIKfyve antagonists, to mitigate mitochondrial fragmentation and improve metabolic function by reducing ceramide levels, enhancing insulin and leptin sensitivity, and decreasing food intake and adiposity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for metabolic disorders, then treatment is provided, but they fail to effectively address mitochondrial dysfunction and leptin resistance

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to address mitochondrial dysfunction and leptin resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent utilizes sphingolipid-like molecules that specifically modulate mitochondrial dynamics parameters (fusion/fission balance) and lipid metabolism parameters (ceramide levels), thereby addressing the underlying mitochondrial dysfunction and leptin resistance that conventional treatments fail to correct

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The sphingolipid-like compounds act as intermediary molecules that mediate between the administered drug and the target biological processes (mitochondrial fusion, ceramide metabolism), enabling effective treatment of metabolic disorders by correcting mitochondrial dysfunction and restoring leptin sensitivity

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If sphingolipid-like molecules are administered, then mitochondrial fragmentation is reversed and metabolic function improves, but the specific molecular mechanism involves complex interactions with ARF6 and PIKfyve

Engineering Contradiction:

Improvereversal of mitochondrial fragmentationVSAvoidmolecular mechanism complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and targets specific molecular components (ARF6, PIKfyve) involved in mitochondrial dynamics regulation, using sphingolipid-like molecules to specifically inhibit these proteins and thereby reverse mitochondrial fragmentation through a defined molecular pathway

Inventive Principle:

Principle #2Taking out (Extraction)

3Use of energy by moving object

If high-fat diet is consumed, then energy intake increases, but mitochondrial fragmentation occurs and leptin resistance develops

Engineering Contradiction:

Improveenergy intakeVSAvoidmitochondrial function and leptin sensitivity

Core Design Contradiction:

Use of energy by moving objectVSReliability

Solution Approach 1:

The sphingolipid-like molecules exert preliminary protective effects by preventing high-fat diet-induced mitochondrial fragmentation and ceramide accumulation before they can establish full leptin resistance, thereby maintaining metabolic sensitivity despite continued high-energy intake

Inventive Principle:

Principle #9Preliminary anti-action

Data Source

PatentUS20220409617A1Drug Formulations and Methods of Treatment for Metabolic Disorders

Publication Date: 2022.12.29 RGT UNIV OF CALIFORNIA

AI summary

Methods of treatment of metabolic disorders with various compounds are provided. Subjects having a metabolic can be administered a sphingolipid-like compound, an ARF6 antagonist, or a PIKfyve antagonist. Formulations and medicaments are utilized to formulate therapeutics that can be administered to individuals as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.